Back to results
US 2016/0256413 A1Published application
Composition and method for treating neurological disease
AssigneeAdamas Pharmaceuticals, Inc.
InventorsGregory T. Went, Timothy J. Fultz, Timothy S. Burkoth
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Claims14
A method comprising:
- orally administering to a human subject with Parkinson's disease a once daily dose consisting of (i) 200 to 500 mg of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient,
- wherein at least one of said excipients is a release modifying excipient, and
- wherein at least 50% of said drug is in an extended release form, and
- wherein administration of the dose once daily provides a steady state plasma concentration of about 3 μM.
1 more element
A method comprising:
- orally administering to a human subject with Parkinson's disease a once daily dose consisting of (i) 200 to 500 mg of a drug selected from the group consisting of amantadine and pharmaceutically acceptable salts thereof, and (ii) at least one excipient,
- wherein at least one of said excipients is a release modifying excipient, and
- wherein at least 50% of said drug is in an extended release form, and
- wherein administration of the dose once daily provides a steady state plasma concentration of about 0.5 μg/ml.
1 more element
Dependencies are inferred from the claim text.